A randomised controlled trial of an automated oxygen delivery algorithm for preterm neonates receiving supplemental oxygen without mechanical ventilation

James Zapata¹, John Jairo Gómez¹, Robinson Araque Campo¹, Alejandro Matiz Rubio¹, Augusto Sola (augustosolaneo@gmail.com)²

¹Grupo de Investigación, Centro Medico Imbanaco, Asociación Atem Health Care, Cali, Colombia
²St Jude Hospital and Masimo Corporation, Irvine, CA, USA

ABSTRACT

Aim: Providing consistent levels of oxygen saturation (SpO₂) in infants in neonatal intensive care units is not easy. This study explored how effectively the Auto-Mixer® algorithm automatically adjusted fraction of inspired oxygen (FiO₂) levels to maintain SpO₂ within an intended range in extremely low birth weight infants receiving supplemental oxygen without mechanical ventilation.

Methods: Twenty extremely low birth weight infants were randomly assigned to the Auto-Mixer® group or the manual intervention group and studied for 12 h. The SpO₂ target was 85–93%, and the outcomes were the percentage of time SpO₂ was within target, SpO₂ variability, SpO₂ >95%, oxygen received and manual interventions.

Results: The percentage of time within intended SpO₂ was 58 ± 4% in the Auto-Mixer® group and 33.7 ± 4.7% in the manual group, SpO₂ >95% was 26.5% vs 54.8%, average SpO₂ and FiO₂ were 89.8% vs 92.2% and 37% vs 44.1%, and manual interventions were 0 vs 80 (p < 0.05). Brief periods of SpO₂ < 85% occurred more frequently in the Auto-Mixer® group.

Conclusion: The Auto-Mixer® effectively increased the percentage of time that SpO₂ was within the intended target range and decreased the time with high SpO₂ in spontaneously breathing extremely low birth weight infants receiving supplemental oxygen.

INTRODUCTION

Oxygen has been used in neonatal intensive care units (NICUs) since the 1940s, and its application was later associated with retinopathy of prematurity (ROP) (1–3). Pulse oximeters that monitor oxygen saturation (SpO₂) have been routinely used in most NICUs since the 1980s to guide manual adjustments of the fraction of inspired oxygen (FiO₂). However, manually controlling FiO₂ is often time-consuming and untimely in preterm infants, which increases the risks of associated side effects affecting the eyes, lungs and central nervous system (4–6). Retinopathy of prematurity is the most important cause of blindness in the city of Cali, Colombia, (7) and accounts for 34% of all blind children in the city.

Despite recently published randomised trials (8–11), we still do not know what the ideal SpO₂ target is for all infants. In extremely low birth weight infants, it seems prudent not to use SpO₂ targets of 85–89% and to avoid SpO₂ above 94%, as it has been reported that the partial pressure of oxygen dissolved in arterial blood was >80 mmHg in 60% of the samples (12). With wide SpO₂ targets that aim to avoid hyperoxia in very low birth weight infants, neonatal morbidity is decreased without a negative effect on mortality or in follow-up (13–18). However, the time spent outside targeted ranges could be high. According to one study performed in infants <28 weeks’ gestation (19), there was significant intercentre variability between

Key notes
- Providing consistent levels of oxygen saturation (SpO₂) for extremely low birth weight infants is not easy.
- This study explored how well the Auto-Mixer® algorithm automatically adjusted fraction of inspired oxygen levels to maintain SpO₂ within an intended range in infants receiving supplemental oxygen without mechanical ventilation.
- The Auto-Mixer® effectively increased the percentage of time that SpO₂ was within the intended target range and decreased the time with high SpO₂.

Abbreviations
CPAP, Continuous positive airway pressure; FiO₂, Fraction of inspired oxygen; NICUs, Neonatal intensive care units; ROP, Retinopathy of prematurity; SpO₂, Oxygen saturation.
intended and actual SpO2 values, with SpO2 levels being above the intended target 30–76% of the time.

In order to decrease adverse effects related to oxygen, the SpO2 and the FiO2 have to be carefully controlled to minimise exposure to hypoxaemia and hyperoxaemia and to significant fluctuation between the two conditions (20). However, SpO2 technology is complex, there are significant differences between SpO2 monitors, and oxygen administration depends completely on the availability, knowledge and experience of the healthcare staff providing the care. Details of systems that can automatically modify FiO2 in infants being mechanically ventilated have been published (21–25), but we still need to assess the efficacy of automated FiO2 adjustment for infants in more stable conditions, who require less-invasive respiratory support (23).

The research group at the Centro Médico Imbanaco in Cali, Colombia, has designed and developed the Auto-Mixer® algorithm, which automatically controls oxygen administration for infants without mechanical ventilation (26). The aim of this proof-of-concept randomised controlled clinical trial was to determine the efficacy of the Auto-Mixer® algorithm, by measuring how it automatically adjusted FiO2 levels to maintain SpO2 within an intended range in preterm infants receiving supplemental oxygen without mechanical ventilation.

METhODS
Automated FiO2 system
The Auto-Mixer® algorithm (Centro Médico Imbanaco, Cali, Colombia), which is shown in Figure 1, analyses the infant’s SpO2 using a monitor with signal extraction technology that automatically identifies motion-associated artefacts and excludes them from analysis (model Rad-9; Masimo Corporation, Irvine, Ca, USA). The Auto-Mixer® then automatically regulates the FiO2 to be administered to the infant, in response to the SpO2 input and the treatment objectives specified by the clinician.

A detailed description of the algorithm has been recently published (26). This study summarises the most salient points.

The Auto-Mixer® algorithm was designed to continuously sense, monitor and process the infant’s SpO2 signal from the Masimo monitor and not to respond immediately to sudden and brief falls in SpO2. The SpO2 signals obtained from a serial port in the monitor are interpreted, stored and digitally processed in an electronic circuit ruled by a microcontroller. This microcontroller then transmits the data, receives the desired parameters set by the user and executes the control actions on the blender. The logic that governs FiO2 adjustments is based on a microprocessor that uses diffuse logic control techniques.

The Auto-Mixer® has an LCD display that allows the user to see the parameters that have been chosen and how much FiO2 has been administered. The parameters that can be selected are: (i) the level of FiO2 at the start of the treatment, (ii) the minimum and maximum SpO2 limits that the healthcare team considers appropriate for the infant (iii) the amount of time that the operator has chosen to respond to the oxygen value (TO2 in Fig 1), ranging from five to 90 sec and (iv) the magnitude of FiO2 increments and decrements, ranging from 1% to 20%. For this study, we selected SpO2 limits of 85% and 93%, as this was what was being used in the NICU, but the clinician could choose any other limits. The time chosen to respond to the oxygen value was set at 10 sec, and the magnitude of FiO2 increments and decrements was set at 1–5%. The microprocessor ‘knows’ the maximum and minimum limits of SpO2 that have been selected and increases or decreases the FiO2 in an attempt to maintain the SpO2 at, or around, the mean value of the limits chosen. The algorithm’s response is directly proportional to the magnitude of the difference between the actual SpO2 and the desired level. The greater the SpO2 difference from the mean, the greater the FiO2 change within the selected magnitude of change selected. Additionally, when SpO2 remains at, or above, the mean of the chosen limits for at least three minutes, the algorithm reduces the FiO2 by 2%. If this change reduces the SpO2 below the mean, the algorithm increases the FiO2 to the previous value. Finally, the Auto-Mixer® has a sound and visual alarm that is activated when the infant is outside the maximum or minimum limit for 40 sec, in case any other complications require immediate action.

Study design and subjects
This was a proof-of-concept randomised trial to evaluate the Auto-Mixer® in extremely low birth weight infants. Infants were included if they were <30 weeks’ gestation and <1000 g at birth, receiving supplemental oxygen by nasal cannula and having episodes of desaturation or hypoxaemia. The infants continued to receive oxygen throughout the 12 h of the study. We did not study infants on mechanical ventilation, those who had congenital abnormalities or if we did not have parental consent.

We estimated that to detect a 20% difference in the percentage of time spent outside the target range, we would need to analyse 100 h of monitoring and care. This calculation was based on published data (19) on the failure rate to maintain the SpO2 target within range during routine care and on our own data. We designed the study
to randomly compare the two groups, and randomisation was carried out using sealed envelopes. Fraction of inspired oxygen was manually adjusted in the control group, which is the traditional routine for neonatal care in our NICU, and in the other group, it was controlled by the Auto-Mixer®. The evaluation period for all the infants was set at 12 h (720 min), and we planned to randomly include 10 infants in each group, so that we could collect a total of 120 h (7200 min) of data for each group.

Because the study did not interfere with clinical care, the clinicians chose whether to deliver low or high flow gas. We acknowledge that the FiO2 at the blender is not the same as the one that the infants' lungs receive, being higher in varying degrees at the blender. The SpO2 target range (85–95%) and the alarm settings (low 84% and high 94%) were the ones that were usually used in the NICU. The primary outcome was the percentage of time that SpO2 was within the desired target range, and the secondary outcomes were nursing interventions, the amount of oxygen received by the infant during the study period and the variability of SpO2.

Oxygen saturation was continuously measured in each infant using the monitor with signal extraction technology, mentioned earlier in this study, which could automatically identify motion-associated SpO2 artefacts and exclude them from analysis. In the control group, the bedside healthcare providers manually adjusted the FiO2 in line with our standard NICU practice. A respiratory therapist researcher checked that all the manual changes were recorded. In the treatment group, the SpO2 values were received by the Auto-Mixer®, which adjusted the FiO2 as previously described. During the 12-h period of the study, we recorded the SpO2 and FiO2 values for each infant in real time, using a computer set-up for this purpose.

The study was approved by the Ethics Committee at Centro Médico Imbanaco in Cali, Colombia, in line with regulatory guidelines from the Ministry of Health of Colombia and the World Principles of Ethics described in the Declaration of Helsinki (revised October 2008).

The neonatal respiratory therapist hired to monitor the trial explained the aim of the study to the parents, and they read the informed consent together. They were reassured that the study was only designed to evaluate the performance of the Auto-Mixer® for 12 h and that this would change the care their infant received. All the study infants were supervised by the respiratory therapist, and the parents were told that there would be no clinical intervention unless any adverse effects were noted with the Auto-Mixer®. The respiratory therapist also ensured that all the equipment – the SpO2 monitors, sensors and Auto-Mixer® computer – were functioning adequately and registered all manual interventions on the blender performed by bedside healthcare providers.

**Statistical methods**

Data were analysed using software SPSS version 19 using descriptive statistics and variability measures to analyse SpO2 dispersion outside the selected range. The Levene's test was utilised to analyse the homogeneity of the variances, and ANOVA was used for comparisons between groups. Statistical significance was set at $p < 0.05$.

**RESULTS**

The study was performed over 11 months in 2011, and 28 newborn infants were eligible to take part. Of these, 20 receiving supplemental oxygen, but not through mechanical ventilation, were included. Eight were not included, three because their parents refused consent and five because investigators were not available. Ten infants were randomised to each group and completed the 12-h study period. There were no significant differences between the groups in mean gestational age (27.5 ± 1.7 vs 27.7 ± 1.7 weeks) and birth weight (785 ± 47.7 vs 763 ± 45.8 g). Postnatal age at the time of the study varied from five to 14 days, as some infants who met the inclusion criteria had previously been on mechanical ventilation, continuous positive airway pressure, oxygen by nasal cannula or no oxygen. The median age was not different between the groups, at 9 days in the manual control group and 8 days in the Auto-Mixer® group. All the infants had experienced at least two daily episodes of hypoxaemia and desaturation before randomisation, ranging from two to 12, with a median of six in both groups, and the episodes of clinically suspected or laboratory confirmed infection were the same (30%). The number of babies receiving high flow oxygen by nasal cannula was similar, with six in the manual control group and five in the Auto-Mixer® group. As this was a short study of only 12 h, we did not collect any long-term hospital or postdischarge data. We recorded data for 720 min for each infant, and this provided 7200 min on the 10 infants with routine manual adjustments and 7200 min on the 10 newborns in the Auto-Mixer® group. We were able to obtain a total of 57 087 reliable data points in the 20 infants: 32 621 in the Auto-Mixer® group and 24 466 in the manual control group. As explained in the methods section, these were due to the fact that, by design, we excluded motion-associated or other SpO2 artefacts. There were also data dropouts, either due to periods of care and/or changes of sensor site.

Table 1 shows the percentage of time that SpO2 was maintained within the intended target, the percentage of time that SpO2 exceeded 95%, the average SpO2 and FiO2 over the 12-h period and SpO2 variability. The differences were statistically significant between the two groups, and SpO2 varied less in the automatic group. The variance in all these findings were detected using Levene's test, with $p = 0.0001$. This confirms that the difference in FiO2 administration between the two methods was genuinely statistically different and not just due to random chance.

The Auto-Mixer® made 7540 automatic FiO2 adjustments during the 12-h period, and the staff made a significantly lower 80 manual oxygen adjustments in the control group and none in the Auto-Mixer® group (Table 1).

Figure 2 shows the comparisons of the percentages of time spent within, below and above the intended SpO2
range. The percentage of time within range was significantly higher in the Auto-Mixer® than in manual care group, and the time above range was significantly lower (p < 0.05). The manual control group spent more time above the intended SpO2 maximum limit, and the most frequent SpO2 values were 96–98%, statistically different from the Auto-Mixer® group. At the lower end of SpO2, the percentage of time with SpO2 under 85% was higher in the automatic group (14%) than the manual group (115%) (p = 0.05). We have information on the frequency of each SpO2 value in 1% increments in both groups, but these data are not shown graphically. There was an overall increased frequency of SpO2 values of 80–85% in the Auto-Mixer® group, but these were of shorter duration, at a median of 7 sec, than the 15 sec in the manual control group. Furthermore, SpO2 values of 80–85% that lasted more than 30 sec, and the frequency of SpO2 values of 70–75% were higher in the manual control group.

**DISCUSSION**

This paper presents a clinical evaluation of the Auto-Mixer® algorithm, which was specifically developed to automatically control FiO2 in preterm infants receiving noninvasive respiratory support and supplemental oxygen. It is based on new-generation, motion-resistant pulse oximetry that can automatically identify motion-associated SpO2 artefacts and exclude them from analysis. The results of this study show that using the Auto-Mixer® improved the proportion of time that infants spent within with SpO2 target, showed less SpO2 variability than the manually controlled method and resulted in NICU staff spending less time manually adjusting FiO2. In addition, the algorithm reduced the percentage of time when SpO2 was over 95%, thereby reducing the frequency and duration of hyperoxic episodes. These data, obtained under routine NICU conditions, suggest that the Auto-Mixer® FiO2 controller improves oxygen administration to preterm infants not on mechanical ventilation, while reducing staff workload.

Despite recently published randomised studies (8–11), the best oxygen profiles to reduce ROP, while optimising preterm infant health and development, remain unknown (27). Periods of hyperoxaemia, and the extent of fluctuations in blood oxygen tension, affect the initiation and progression of ROP (28–31). Both hypoaxaemia and hyperoxaemia occur frequently in clinical practice during routine manual FiO2 control, suggesting that differences in clinical practice may account for different incidences of ROP. This is a global problem of different magnitude in different units. Finding out how to increase the percentage of time spent within intended SpO2 targets and diminishing wide SpO2 fluctuations could be advantageous to neonatal care and outcomes. The Auto-Mixer® proved effective at doing that in spontaneously breathing infants. The clinical high and low SpO2 limits can be freely configured with this FiO2 controller software and can therefore be adapted to any clinical targets.

Several studies have tested different automatic FiO2 control systems (21–23) and compared routine optimal manual adjustments and automatic control in ventilated infants. The present study used a different algorithm and was carried out in infants receiving oxygen and not mechanical ventilation.

As described in the results, using the algorithm increased the percentage of time with SpO2 of <85%, an increase that has been noted in studies with other equipment. In this study, the episodes of SpO2 80–85% in the algorithm group occurred more frequently but were shorter than those in the manual control group. Furthermore, prolonged episodes with automated FiO2 adjustment were less frequent, and the number of episodes of more significant hypoxaemia (SpO2 70–75%) were less frequent in the algorithm than manual control group. The impact of frequency and duration on desaturation is currently being investigated. It is not clearly known whether frequent but brief desaturations are more detrimental than less frequent, prolonged desaturations, but

---

**Table 1 Oxygen control over the 120 h in the two groups receiving noninvasive oxygen therapy**

| Percentage of time | Auto-Mixer | Blender-manual routine care | p-value |
|--------------------|------------|-----------------------------|---------|
| with SpO2 maintained within target | 58 ± 4% | 33.7 ± 4.7% | <0.01 |
| with SpO2 >95% | 26.5% | 54.8% | <0.01 |
| 12-h SpO2 (%) | 89.8 | 92.2 | <0.05 |
| SpO2 variability (%) | 5.7 | 6.3 | <0.05 |
| 12-h FiO2 (%) | 37 | 44 | <0.01 |
| Manual interventions | 0 | 80 | <0.001 |

SpO2, Oxygen saturation.

**Figure 2** Percentage of time spent below, within and above the intended oxygen saturation (SpO2) range with the Auto-Mixer (AM) and manual routine care (blender).

©2014 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica. 2014 103, pp. 928–933
the severity of hypoxaemia, with lower SpO2 values during desaturations, is likely to have a worse impact.

It has been shown that maintaining higher basal SpO2 values is an effective way of reducing episodes of decreased SpO2, but at a cost of increased oxygen exposure (32). Preventing or decreasing episodes of SpO2 80–85% can be achieved using the algorithm in different ways. One is setting a higher SpO2 value for the low limit. Another is providing higher FiO2 and/or tolerating higher SpO2 values, but this may be associated with more time exposed to hyperoxia, with its associated severe risks. Although selecting FiO2 increments higher than the 1–5% used in this study may prove useful, this was not evaluated. However, increasing FiO2 rapidly, and by greater amounts in response to short events, may be inappropriate and could increase the risk over overshooting and increasing the frequency of SpO2 fluctuations. For this reason, the algorithm was designed to not to respond immediately to sudden and brief falls in SpO2. Manual care intervention may be a solution in such cases, such as changing the infant’s position, reconnecting the tube or stimulation in the case of apnoea. Automated FiO2 adjustment should never be a substitute for close and mandatory clinical supervision and more appropriate interventions based on the clinical assessment of each individual situation in each individual baby.

In our study, 55% of the SpO2 values were more than 93% in the control group, which is similar to the 36–70% reported by other studies, which included infants on mechanical ventilation, for the proportion of time with saturations over the target range (19,23). Greater intercentre variability in achieved versus intended pulse oximeter saturation has also been described (19). The precision targeting of SpO2 in preterm infants on continuous positive airway pressure (CPAP) was reported, for the first time, by Lim et al. (33). When they required supplemental oxygen, these infants were outside the target SpO2 range for 69% of the total recording time and had 48 episodes of severe hyperoxia (SpO2 >98%) in 24 h (33). In another recent study, where the prevalence of ROP was reduced, without increasing mortality, using SpO2 targets of 85–95%, the data showed that some infants spent at least 50% of the 24-h period above that range (34). These recent studies (33–35) are comparable to the findings in the control group in our current study. Furthermore, FiO2 was adjusted an average of 25 times per day and, when each nurse was caring for more patients, the frequency of prolonged hyperoxia increased (33).

This study had some limitations. It is very difficult to mask a study like this and, by design, this study was not masked. However, all the recorded data were analysed without the participation of the investigators. In addition, we followed routine NICU procedures for clinical care, oxygen administration, SpO2 targets and the nursing to patient ratio. Altering this may have modified the percentage of time that infants spent within the intended SpO2 target and with SpO2 >95%. The strength of the study, on the other hand, is that it is a randomised study comparing a newly developed tool in extremely low birth weight infants, who are receiving oxygen but are not on mechanical ventilation.

CONCLUSIONS

This randomised study was carried out under routine NICU conditions in preterm infants, who were breathing spontaneously, required oxygen and demonstrated frequent fluctuations in SpO2. It showed that when FiO2 was adjusted automatically, the intended SpO2 target was better maintained, and there was less exposure to high SpO2 values. At the same time, the Auto-Mixer® algorithm reduced FiO2 requirements and the need for staff intervention, compensating for some of the limitations that presently exist with conventional forms of noninvasive oxygen administration. These effects were accompanied by more frequent, but shorter-lived, episodes that increased the overall percentage of time with SpO2 at 80–85%. We believe that the automatic control algorithm used in this study is cost-effective and may decrease the rates of neonatal conditions and morbidity associated with unnecessarily high exposure to oxygen, large fluctuations in oxygen levels, hyperoxaemia and increased radical oxygen species. These reductions are of benefit to the individual infant, their family and society as a whole. Further research is needed to determine the algorithm’s impact on the long-term respiratory, ophthalmic and neurologic outcomes of preterm infants.

ACKNOWLEDGEMENTS

We are grateful for the support provided by the medical and administrative personnel at Centro Médico Imbanaco of Cali, Colombia, in particular the respiratory therapy department and the ethics and research committee. We are also grateful to Dr Claudia Zuluaga (Ophthalmology) for her collaboration and support and to Dr Reinaldo Carvajal for his statistical support in design and analysis.

FUNDING

The study was partly funded by the Department of Science, Technology and Innovation COLCIENCIAS in Colombia and Centro Médico Imbanaco, Cali, Colombia. The study sponsors had no role in study design, collection, analysis and interpretation of data or in the writing of the report.

CONFLICTS OF INTEREST

The Auto-Mixer® algorithm for the automated adjustment of FiO2 was developed in Cali, Colombia, and patented by James Zapata, Robinson Araque Campo and Alejandro Matiz Rubio, who also hold the intellectual rights. Augusto Sola became a part-time employee at the Masimo Corporation, Irvine, California, USA, which produces the signal extraction technology used by the Auto-Mixer®, in January 2013, after the work in this paper was completed. No author or individual received an honorarium, grant or other form of payment to produce the manuscript.
References

1. Silverman WA. Retrolental fibroplasia: a modern parable. New York: Grune and Stratton, 1980.
2. Silverman WA. ROP forme fruste. *J Perinatol* 2001; 21: 393–4.
3. Cross KW. Cost of prevention of retrolental fibrosis? *Lancet* 1973; 2: 954–6.
4. Sola A, Rogido MR, Deulofeut R. Oxygen as a neonatal health hazard: call for detente in clinical practice. *Acta Paediatr* 2007; 96: 801–12.
5. Sola A. Oxygen in neonatal anesthesia: friend or foe? *Curr Opin Anaesthesiol* 2008; 21: 332–9.
6. DeMauro SB, Roberts RS, Davis P, Alvaro R, Bairam A, Schmidt B. Impact of delivery room resuscitation on outcomes up to 18 months in very low birth weight infants. *J Pediatr* 2011; 159: 546–50.
7. Zuluaga C. Causas de ceguera infantil en Cali. *Colomb Med* 2005; 36: 235–8.
8. Schmidt B, Whyte RK, Asztalos EV, Moddemann D, Poets C, Rabi Y, et al. Canadian Oxygen Trial (COT) Group. Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial. *JAMA* 2013; 309: 2111–20.
9. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Target ranges of oxygen saturation in extremely preterm infants. *N Engl J Med* 2010; 362: 1959–69.
10. BOOST II United Kingdom Collaborative Group, BOOST II Australia Collaborative Group, BOOST II New Zealand Collaborative Group, Stenson BJ, Tarnow-Mordi WO, Darlow BA, et al. Oxygen saturation and outcomes in preterm infants. *N Engl J Med* 2013; 368: 2094–104.
11. Vaucher YE, Peralta-Carcelen M, Finer NN, Carlo WA, Gantz MG, Walsh MC, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. *N Engl J Med* 2012; 367: 2495–504.
12. Castillo A, Sola A, Baquero H, Neira F, Alvis R, Deulofeut R, et al. Pulse oxygen saturation levels and arterial oxygen tension values in newborns receiving oxygen therapy in the neonatal intensive care unit: is 85% to 93% an acceptable range? *Pediatrics* 2008; 121: 882–9.
13. Chow LC, Wright KW, Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? *Pediatrics* 2003; 111: 339–45.
14. Wright KN, Sami A, Thompson L, Ramanathan R, Roy J, Farzavandi S. A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity. *Trans Am Ophthalmol Soc* 2006; 104: 78–84.
15. Deulofeut R, Critz A, Adams-Chapman I, Sola A. Avoiding hyperoxia in infants <1250 g is associated with improved short- and long-term outcomes. *J Perinatol* 2006; 26: 700–5.
16. Saugstad OD, Speer CP, Halliday HL. Oxygen saturation in immature babies: revisited with updated recommendations. *Neonatology* 2011; 100: 217–8.
17. Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G. A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. *Ophthalmology* 2009; 116: 513–8.
18. Vanderveen DK, Mansfield TA, Eichenwald EC. Lower oxygen saturation alarm limits decrease the severity of retinopathy of prematurity. *J AAPOS* 2006; 10: 445–8.
19. Hagadorn JI, Furey AM, Nghiem TH, Schmid CH, Phelps DL, Pillers DA, et al. Achieved versus intended pulse oximeter saturation in infants born less than 28 weeks’ gestation: the AVIOx study. *Pediatrics* 2006; 118: 1574–82.
20. Hartnett ME, Lane RH. Effects of oxygen on the development and severity of retinopathy of prematurity. *J AAPOS* 2013; 17: 229–34.
21. Urschitz M, Horn M, Seyfang A, Hallenberger A, Herberts T, Miksch S, et al. Automatic control of the inspired oxygen fraction in preterm infants: a randomized crossover trial. *Am J Respir Crit Care Med* 2004; 170: 1095–100.
22. Claire N, D’Ugar C, Bancalari E. Automated adjustment of inspired oxygen in preterm infants with frequent fluctuations in oxygenation: a pilot clinical trial. *J Pediatr* 2009; 155: 640–5.
23. Claire N, Bancalari E, D’Ugar C, Nelín L, Stein M, Ramanathan R, et al. Multicenter crossover study of automated control of inspired oxygen in ventilated preterm infants. *Pediatrics* 2011; 127: e76–83.
24. Claire N, Bancalari E. Automated closed loop control of inspired oxygen concentration. *Respir Care* 2013; 58: 151–61.
25. Claire N, Bancalari E. Role of automation in neonatal respiratory support. *J Perinat Med* 2013; 41: 115–8.
26. Matiz A, Araque R, Zapata J. Auto-mixer: equipment for the reduction of risks associated with inadequate oxygen supply. *Ing Investig* 2014; 34: 60–5.
27. Sola A, Zuluaga C. Effects of oxygen on the development and severity of retinopathy of prematurity. *J AAPOS* 2013; 17: 650–2.
28. Morozoff PE, Evans RW. Closed-loop control of SaO2 in the neonate. *Biomed Instrum Technol* 1992; 26: 117–23.
29. Cunningham S, Fleck BW, Elton RA, McIntosh N. Transcutaneous oxygen levels in retinopathy of prematurity. *Lancet* 1995; 346: 1464–5.
30. Saito Y, Omoto T, Cho Y, Hatsu kawa Y, Fujimura M, Takeuchi T. The progression of retinopathy of prematurity and fluctuation in blood gas tension. *Graefes Arch Clin Exp Ophthalmol* 1995; 231: 151–6.
31. Penn JS, Henry MM, Wall PT, Tolman BL. The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats. *Invest Ophthalmol Vis Sci* 1995; 36: 2063–70.
32. McEvoy C, Durand M, Hewlett V. Episodes of spontaneous desaturations in infants with chronic lung disease at two different levels of oxygenation. *Pediatr Pulmonol* 1993; 15: 140–4.
33. Lim K, Wheeler KL, Gale TJ, Jackson HD, Kihlstrand JF, Sand C, et al. Oxygen saturation targeting in preterm infants receiving continuous positive airway pressure. *J Pediatr* 2014; 164(730–736): e1.
34. Bizzarro MJ, Li FY, Katz K, Shabanova V, Ehrenkranz RA, Bhandari V. Temporal quantification of oxygen saturation ranges: an effort to reduce hyperoxia in the neonatal intensive care unit. *J Perinat Med* 2014; 34; 33–8.
35. Wallace DK, Veness-Meehan KA, Miller WC. Incidence of severe retinopathy of prematurity before and after a modest reduction in target oxygen saturation levels. *J AAPOS* 2007; 11: 170–4.